Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics
Preprint
Abstract
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease characterized by cystic destruction and metastatic growth of smooth muscle-like cells. Despite advances in understanding its genetic basis, the cellular heterogeneity, regulatory mechanisms, and microenvironmental interactions driving LAM progression remain poorly defined. In this study, we employed an integrative multi-omics approach combining single-cell RNA sequencing (scRNA-seq), single-nucleus ATAC sequencing (snATAC-seq), and high-resolution spatial transcriptomics (Visium, Visium HD, and Xenium) to decode the LAM niche in its native environment. We identified two spatially and functionally distinct LAM subtypes: LAM CORE1 and LAM CORE2 . LAM CORE1 cells exhibited a uterine smooth muscle-like phenotype, expressing associated markers ( ACTA2 , MYH11 ) and were enriched in MTORC1 signaling and myogenic pathways, supporting a uterine origin. In contrast, LAM CORE2 cells displayed fibroblast-like features, with upregulated extracellular matrix (ECM) remodeling genes ( COL1A1 , MMP11 ) and epithelial-to-mesenchymal transition (EMT) pathways, suggesting a role in niche formation. Pseudotime and regulon analyses revealed dynamic transitions between these subtypes, driven by distinct transcriptional networks (e.g., HOX/PBX in LAM CORE1 , TWIST/ZEB in LAM CORE2 ). The presence of the two distinct LAM subtypes was further validated by RNAscope and immunofluorescence microscopy. We identified LAM-associated fibroblasts (LAFs) as activated stromal cells expressing canonical markers ( FAP , S100A4 , VIM, IGFBP7, SPARC ) and localized within LAM lesions. Subpopulations of LAFs, LAF-seed (proximal to LAM CORE1 ) and LAF-niche (surrounding LAM niches), exhibited unique functional profiles, including ECM deposition, TGF-β signaling, and myofibroblast activation. Regulatory network analysis pinpointed EGR1 as a central hub governing LAF phenotype. Our comprehensive spatial profiling revealed niche structures dominated by LAM CORE1 cells and surrounded by lymphatic endothelial cells (LECs), LAFs, scattered LAM CORE2 cells, macrophages, and reprogrammed alveolar epithelial cells (AT2). ECM remodeling and aberrant organization of cable-like structures (α-smooth muscle actin+) of the LAM niches were further validated by second harmonic generation microscopy. These findings provide a high-resolution blueprint of LAM pathogenesis, highlighting the interplay between uterine-derived LAM CORE cells, activated fibroblasts, and the remodeled lung microenvironment. They significantly enhance our understanding of the LAM niche microenvironment and offer insights into potential therapeutic targets and strategies for managing this complex disease.Keywords
Funding Information
- NHLBI (R01HL153045)
- NHLBI (R01 HL172914)
- NHLBI (U01 HL175383)
- NHLBI (U01HL148856)
- The LAM Foundation (LAM0150C01-22)
- The LAM Foundation (LAM0155S01-22)
- The LAM Foundation (LAM0164E01-1177076-24)
- The LAM Foundation (LAMF165EI-1346848-25)
This publication has 78 references indexed in Scilit:
- Bidirectional activation of stem-like programs between metastatic cancer and alveolar type 2 cells within the nicheDevelopmental Cell, 2024
- Cellular senescence in chronic lung diseases from newborns to the elderly: An update literature reviewBiomedicine & Pharmacotherapy, 2024
- EGR1 Mediated Reduction of Fibroblast Secreted-TGF-β1 Exacerbated CD8+ T Cell Inflammation and Migration in VitiligoInflammation, 2023
- Integrated analysis of multimodal single-cell dataCell, 2021
- Macrophages and Therapeutic Resistance in CancerCancer Cell, 2015
- Computed tomographic features of lymphangioleiomyomatosis: Evaluation in 138 patientsEuropean Journal of Radiology, 2015
- The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cellsNature Biotechnology, 2014
- Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialThe Lancet Respiratory Medicine, 2013
- The Genotype-Tissue Expression (GTEx) projectNature Genetics, 2013
- RNAscopeThe Journal of Molecular Diagnostics, 2012